secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0000950170-23-016250
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights
--------------------------------------------------------------------------------

- Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.
- Royalties on net sales range from mid-teens to high-teens; no milestone payments are required.
- Initial focus: cerebral cavernous malformations and seizure disorders; GV101 is in Phase 1.
- Graviton conducts development through Phase 2; Ovid handles post-Phase 2 development and commercialization worldwide except China, Hong Kong, Macau, Taiwan.
- Ovid CEO Dr. Jeremy Levin will join Graviton's Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/0000950170-23-016250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023016250/ovid-20230501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer